Logo image of ADN

ADVENT TECHNOLOGIES HOLDINGS (ADN) Stock Fundamental Analysis

NASDAQ:ADN - Nasdaq - US00788A2042 - Common Stock - Currency: USD

2.31  +0.22 (+10.53%)

Fundamental Rating

2

ADN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 95 industry peers in the Electrical Equipment industry. ADN has a bad profitability rating. Also its financial health evaluation is rather negative. ADN shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ADN has reported negative net income.
ADN had a negative operating cash flow in the past year.
In the past 5 years ADN always reported negative net income.
In the past 5 years ADN always reported negative operating cash flow.
ADN Yearly Net Income VS EBIT VS OCF VS FCFADN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

ADN has a worse Return On Assets (-885.29%) than 95.79% of its industry peers.
Industry RankSector Rank
ROA -885.29%
ROE N/A
ROIC N/A
ROA(3y)-100.37%
ROA(5y)-96.93%
ROE(3y)-220.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADN Yearly ROA, ROE, ROICADN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ADN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADN Yearly Profit, Operating, Gross MarginsADN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -500 -1K

More info and screens

0

2. Health

2.1 Basic Checks

ADN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADN has more shares outstanding
The number of shares outstanding for ADN has been increased compared to 5 years ago.
ADN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ADN Yearly Shares OutstandingADN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M
ADN Yearly Total Debt VS Total AssetsADN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

ADN has an Altman-Z score of -63.95. This is a bad value and indicates that ADN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -63.95, ADN is doing worse than 94.74% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -63.95
ROIC/WACCN/A
WACC9.12%
ADN Yearly LT Debt VS Equity VS FCFADN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

ADN has a Current Ratio of 0.06. This is a bad value and indicates that ADN is not financially healthy enough and could expect problems in meeting its short term obligations.
ADN has a worse Current ratio (0.06) than 93.68% of its industry peers.
A Quick Ratio of 0.05 indicates that ADN may have some problems paying its short term obligations.
ADN's Quick ratio of 0.05 is on the low side compared to the rest of the industry. ADN is outperformed by 93.68% of its industry peers.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.05
ADN Yearly Current Assets VS Current LiabilitesADN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

ADN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.87%, which is quite impressive.
The Revenue has grown by 10.92% in the past year. This is quite good.
Measured over the past years, ADN shows a very strong growth in Revenue. The Revenue has been growing by 67.03% on average per year.
EPS 1Y (TTM)48.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.19%
Revenue 1Y (TTM)10.92%
Revenue growth 3Y76.57%
Revenue growth 5Y67.03%
Sales Q2Q%-89.84%

3.2 Future

Based on estimates for the next years, ADN will show a very strong growth in Earnings Per Share. The EPS will grow by 44.75% on average per year.
Based on estimates for the next years, ADN will show a very strong growth in Revenue. The Revenue will grow by 633.14% on average per year.
EPS Next Y98.1%
EPS Next 2Y44.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2705.94%
Revenue Next 2Y633.14%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ADN Yearly Revenue VS EstimatesADN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ADN Yearly EPS VS EstimatesADN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 0 -5 -10 -15 -20

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADN. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 22.87, ADN is valued on the expensive side.
Based on the Price/Forward Earnings ratio, ADN is valued a bit cheaper than 75.79% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.94. ADN is around the same levels.
Industry RankSector Rank
PE N/A
Fwd PE 22.87
ADN Price Earnings VS Forward Price EarningsADN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADN Per share dataADN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20 -25

4.3 Compensation for Growth

ADN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ADN's earnings are expected to grow with 44.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.75%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ADN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADVENT TECHNOLOGIES HOLDINGS

NASDAQ:ADN (5/22/2025, 2:26:58 PM)

2.31

+0.22 (+10.53%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryElectrical Equipment
Earnings (Last)11-25 2024-11-25
Earnings (Next)08-11 2025-08-11/amc
Inst Owners6.44%
Inst Owner Change-87.82%
Ins Owners9.21%
Ins Owner Change0%
Market Cap6.10M
Analysts45
Price TargetN/A
Short Float %1.86%
Short Ratio1.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 22.87
P/S 1.04
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-26.95
EYN/A
EPS(NY)0.1
Fwd EY4.37%
FCF(TTM)-4.03
FCFYN/A
OCF(TTM)-3.96
OCFYN/A
SpS2.23
BVpS-6.85
TBVpS-6.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -885.29%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-100.37%
ROA(5y)-96.93%
ROE(3y)-220.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.74%
Cap/Sales 2.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.05
Altman-Z -63.95
F-Score3
WACC9.12%
ROIC/WACCN/A
Cap/Depr(3y)197.26%
Cap/Depr(5y)268.79%
Cap/Sales(3y)91.22%
Cap/Sales(5y)58.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.19%
EPS Next Y98.1%
EPS Next 2Y44.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)10.92%
Revenue growth 3Y76.57%
Revenue growth 5Y67.03%
Sales Q2Q%-89.84%
Revenue Next Year2705.94%
Revenue Next 2Y633.14%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year98.39%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y77.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.84%
OCF growth 3YN/A
OCF growth 5YN/A